Ligand Pharmaceuticals Incorporated (LGND) is listed on NASDAQ in Pharmaceutical Stocks. It is $280.77, -1.32%, with a $5.6B market cap. RSI is 42.4, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 42.4 Neutral
Market Cap $5.6B
Volume 107.9K
Fundamentals — 10-Q Q2 2026
Revenue $115.4M
Net Income $35.2M
EPS $1.63
Operating Margin 22.5%
Net Margin 30.5%
Debt / Equity 1.2x
P/E Ratio 172.3x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Espinoza Octavio | Chief Financial Officer | Sell | 31,641 | $292.06 | $9.2M | 2026 Aug 12 |
| Haas Jason | Director | Sell | 7,138 | $292.81 | $2.1M | 2026 Aug 12 |
| Reardon Andrew | CLO & Secretary | Sell | 5,000 | $288.99 | $1.4M | 2026 Aug 3 |
| Reardon Andrew | CLO & Secretary | Sell | 5,000 | $313.28 | $1.6M | 2026 Jul 1 |
| Sabba Stephen L | Director | Sell | 2,145 | $254.00 | $544,830 | 2026 Jun 16 |
| Haas Jason | Director | Sell | 6,461 | $255.58 | $1.7M | 2026 Jun 12 |
| Aryeh Jason | Director | Sell | 5,000 | $250.00 | $1.3M | 2026 Jun 11 |
| Lamattina John L | Director | Sell | 4,591 | $250.88 | $1.2M | 2026 Jun 10 |
| Reardon Andrew | CLO & Secretary | Sell | 5,000 | $227.06 | $1.1M | 2026 Jun 1 |
| Kozarich John W | Director | Sell | 2,501 | $225.14 | $563,080 | 2026 May 13 |
| Reardon Andrew | CLO & Secretary | Sell | 5,000 | $231.31 | $1.2M | 2026 May 1 |
| Kozarich John W | Director | Sell | 467 | $202.23 | $94,440 | 2026 Apr 1 |
| Reardon Andrew | CLO & Secretary | Sell | 5,000 | $201.24 | $1.0M | 2026 Apr 1 |
| Sabba Stephen L | Director | Sell | 1,000 | $207.87 | $207,873 | 2026 Mar 23 |
| Espinoza Octavio | Chief Financial Officer | Sell | 3,057 | $225.00 | $687,825 | 2026 Mar 11 |
| Lamattina John L | Director | Sell | 2,161 | $200.76 | $433,842 | 2026 Mar 6 |
| Reardon Andrew | CLO & Secretary | Sell | 5,000 | $206.35 | $1.0M | 2026 Mar 4 |
| Espinoza Octavio | Chief Financial Officer | Sell | 13,423 | $205.83 | $2.8M | 2026 Mar 4 |
| Sabba Stephen L | Director | Sell | 2,034 | $201.50 | $409,851 | 2026 Mar 3 |
| Kozarich John W | Director | Sell | 467 | $200.50 | $93,632 | 2026 Mar 2 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $34.67 | 38.7 | $6.0B |
| | $40.94 | 41.9 | $5.5B |
| | $91.15 | 37.5 | $6.0B |
| | $65.68 | 62.9 | $6.2B |
| | $144.22 | 47.1 | $9.3B |
Take LGND further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put LGND in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Ligand Pharmaceuticals Incorporated next reports.
Set alerts on LGND
Get notified when Ligand Pharmaceuticals Incorporated hits your price targets or technical conditions are met.
Get Started Free